aUp to 270 days of low-dose ruxolitinib or up to 90 days of any JAK inhibitor.
bA 2-week washout will be required for MF directed therapy and at least 28 days for experimental MF therapies.
cPhysician’s Choice therapy includes low-dose ruxolitinib (no more than 10 mg/day), danazol, corticosteroids, or hydroxyurea.
BID=twice daily; DIPSS=Dynamic International Prognostic Scoring System; JAK=Janus kinase; MF=myelo brosis; PET-MF=post-essential thrombocythemia MF; PGIC=patient global impression of change; PMF=primary MF; PPV-MF=post-polycythemia vera MF; SVR=spleen volume reduction; TSS=total symptom score.
*Current or prior JAK2 inhibitor patients may be eligible if this treatment meets at least one of the following criteria:
Prior treatment with any JAK2 inhibitor, irrespective of dose, with a duration of 90 days or less.
Prior treatment with ruxolitinib, at no more than 10 mg total daily dose on any day, with a duration of 270 days or less.
© Copyright 2023 CTI BioPharma Corp.